. 2010.
. 2007.
“Safety Evaluation Of Nonoxynol-9 Gel In Women At Low Risk Of Hiv Infection.”. Aids 12 (4). Aids: 433-7. doi:10.1097/00002030-199804000-00013.
. 1998. “Safety Evaluation Of Nonoxynol-9 Gel In Women At Low Risk Of Hiv Infection”. Aids 12. Aids: 433-7.
. 1998. . 2010.
. 2008.
. 1998.
“Protection Against Sexually Transmitted Diseases By Granting Sex Workers In Thailand The Choice Of Using The Male Or Female Condom: Results From A Randomized Controlled Trial.”. Aids 12 (14). Aids: 1851-9. doi:10.1097/00002030-199814000-00017.
. 1998. “A Phase I Double Blind, Placebo-Controlled, Randomized Study Of The Safety And Immunogenicity Of An Adjuvanted Hiv-1 Gag-Pol-Nef Fusion Protein And Adenovirus 35 Gag-Rt-Int-Nef Vaccine In Healthy Hiv-Uninfected African Adults”. Plos One 10. Plos One: e0125954. http://www.ncbi.nlm.nih.gov/pubmed/25961283.
. 2015. . 2010.
. 1995.
“Lessons From Iavi-006, A Phase I Clinical Trial To Evaluate The Safety And Immunogenicity Of The Pthr.hiva Dna And Mva.hiva Vaccines In A Prime-Boost Strategy To Induce Hiv-1 Specific T-Cell Responses In Healthy Volunteers.”. Vaccine 26 (51). Vaccine: 6671-7. doi:10.1016/j.vaccine.2008.09.016.
. 2008. “Induction Of Multifunctional Human Immunodeficiency Virus Type 1 (Hiv-1)-Specific T Cells Capable Of Proliferation In Healthy Subjects By Using A Prime-Boost Regimen Of Dna-And Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes”. J Virol 80. J Virol: 4717-4728. http://www.ncbi.nlm.nih.gov/pubmed/16641265.
. 2006. “Does Malnutrition Affect Survival In Cirrhosis? Pinc (Policentrica Italiana Nutrizione Cirrosi).”. Hepatology 23 (5). Hepatology: 1041-6. doi:10.1002/hep.510230516.
. 1996. “Clinical And Immuno-Virologic Characterization Of The Efficacy Of Stavudine, Lamivudine, And Indinavir In Human Immunodeficiency Virus Infection”. J Pediatric 135. J Pediatric: 675-82.
. 1999. “Clinical And Immuno-Virologic Characterization Of The Efficacy Of Stavudine, Lamivudine, And Indinavir In Human Immunodeficiency Virus Infection.”. J Pediatr 135 (6). J Pediatr: 675-82. doi:10.1016/s0022-3476(99)70084-3.
. 1999. “Cancer Prevalence In Italian Regions With Local Cancer Registries”. Tumori 85. Tumori: 400-7.
. 1999. . 2008.
“The Advanced Glaucoma Intervention Study (Agis): 14. Distinguishing Progression Of Glaucoma From Visual Field Fluctuations”. Ophthalmology 111. Ophthalmology: 2109-2116. http://www.ncbi.nlm.nih.gov/pubmed/15522379.
. 2004. “Safety And Immunogenicity Of Vrc Multiclade Hiv-1 Adenoviral Vector Vaccine Alone Or With Vrc Multiclade Hiv-1 Dna Plasmid Vaccine In The African Adults”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. “Safety And Immunogenicity Of Mva.hiva By 3 Different Routes”. In Aids Vaccine 2005 International Conference. Aids Vaccine 2005 International Conference. Montreal, Quebec, Canada.
. 2005. “Phase 2A Dose And Route Study Of A Dna Prime Mva Boost Vaccine Candidate”. In Aids Vaccine 2005 International Conference. Aids Vaccine 2005 International Conference. Montreal, Quebec, Canada.
. 2005. “A Phase 2 Study To Evaluate The Safety And Immunogenicity Of A Recombinant Adeno-Associated Virus Hiv Vaccine”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. “A Cross-Sectional Study In Eastern And Southern Africa To Characterize Laboratory Reference Intervals In Healthy Adults For Hiv Prevention Trials”. In Aids Vaccine 2008 Conference. Aids Vaccine 2008 Conference. Cape Town, South Africa. http://www.vaccineenterprise.org/conference_archive/2008/index.html.
. 2008.